Prostate Cell News Volume 13.08 | Mar 4 2022

    By
    Justin.choi
    -
    0
    14







    2022-03-04 | PCN 13.08


    Prostate Cell News by STEMCELL Technologies
    Vol. 13.08 – 4 March, 2022
    TOP STORY

    Novel Circular RNA circ_0086722 Drives Tumor Progression by Regulating the miR-339-5p/STAT5A Axis in Prostate Cancer

    In vivo and in vitro experiments were performed to evaluate the functions of circ_0086722 in prostate cancer.
    [Cancer Letters]

    Abstract
    ON987CXN-mar-728x90-2022
    PUBLICATIONSRanked by the impact factor of the journal

    miR-32 Promotes MYC-Driven Prostate Cancer

    Scientists showed that miR-32 promoted MYC-induced prostate adenocarcinoma and identified PDK4 as a prostate cancer-relevant metabolic target of miR-32-3p.
    [Oncogenesis]

    Full Article

    Redox-Responsive Nanoparticles Enhance Radiation Therapy by Altering Multifaceted Radio-Resistance Mechanisms in Human Castration-Resistant Prostate Cancer Cells and Xenografts

    The authors investigated the effect of a novel oxygen-generating polymer-lipid manganese dioxide nanoparticle on improving radiation therapy (RT) outcomes in CRPC xenograft models by modulating the tumor microenvironment both before and after RT.
    [Radiotherapy and Oncology]

    Abstract

    TRPM2-AS Promotes Paclitaxel Resistance in Prostate Cancer by Regulating FOXK1 via Sponging miR-497-5p

    Transient receptor potential cation channel subfamily M member 2 antisense RNA (TRPM2-AS) knockdown suppressed cell progression and paclitaxel (PTX) resistance in PTX-resistant prostate cancer cells by miR-497-5p/FOXK1 axis.
    [Drug Development Research]

    Abstract

    Pan-Cancer Analysis Identifies LMNB1 as a Target to Redress Th1/Th2 Imbalance and Enhance PARP Inhibitor Response in Human Cancers

    In vitro experiments revealed that targeting LMNB1 had a synergistic effect on prostate cancer with poly ADP-ribose polymerase (PARP) inhibitor treatment.
    [Cancer Cell International]

    Full Article

    OTUD6A Promotes Prostate Tumorigenesis via Deubiquitinating Brg1 and AR

    Researchers observed that several ovarian tumor members displayed genomic amplification in prostate cancer, among which ovarian tumor deubiquitinase 6A (OTUD6A) amplified in the top around 15–20%.
    [Communications Biology]

    Full Article

    Radiotherapy Alters Expression of Molecular Targets in Prostate Cancer in a Fractionation- and Time-Dependent Manner

    The authors irradiated prostate cancer cells either with a single dose of 10 Gy x-ray or a multifractionated regimen with ten fractions of 1 Gy.
    [Scientific Reports]

    Full Article

    LXA4 Enhances Prostate Cancer Progression by Facilitating M2 Macrophage Polarization via Inhibition of METTL3

    Scientists showed that downregulation of METTL3 in prostate cancer tumor-associated macrophages modulated macrophages toward an M2-like phenotype and that this modulation was mediated by activation of STAT6.
    [International Immunopharmacology]

    Full Article

    βArrestin1 Regulates Glucocorticoid Receptor Mitogenic Signaling in Castration-Resistant Prostate Cancer

    Depletion of βarrestin1 in androgen receptor-null CRPC cells inhibited glucocorticoid receptor function and CRPC growth and invasion in both in vitro and in vivo settings.
    [Prostate]

    Abstract

    Circ_0076305 Facilitates Prostate Cancer Development via Sponging miR-411-5p and Regulating PGK1

    Circ_0076305 served as a novel oncogene prostate cancer progression through regulation of miR-411-5p/phosphoglycerate kinase 1 (PGK1) axis.
    [andrology]

    Abstract
    Explore Antibodies for Epithelial Cell Markers
    REVIEWS

    The Role of Genetic Testing in Prostate Cancer Screening, Diagnosis, and Treatment

    The authors provide an overview of the current role of genetic testing in prostate cancer screening, diagnosis, and treatment.
    [Current Opinion in Oncology]

    Abstract
    INDUSTRY AND POLICY NEWS

    NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

    Nymox Pharmaceutical Corporation announced that it has submitted the company’s NDA to the FDA for Fexapotide Triflutate to seek marketing approval in the US for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia.
    [Nymox Pharmaceutical Corporation (GlobeNewswire, Inc.)]

    Press Release
    FEATURED EVENT

    13th Online Dutch Stem Cell Meeting

    April 16, 2022
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Prostate Cancer Progression

    The University of British Columbia – Vancouver, British Columbia, Canada

    Research Associate – Profiling of Solid Tumors

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Associate – Cell Viability

    Singapore-MIT Alliance for Research and Technology (SMART) Centre – Singapore, Singapore

    Postdoctoral Research Associate – Cancer Research

    University of Nebraska Medical Center – Omaha, Nebraska, United States

    Postdoctoral Positions – Translational 3D Pathology

    University of Washington – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter